Merus: Great European Oncology Developer, But Properly Valued
Merus NV has seen a significant increase in market cap from $852mn to $3.46bn in the past year. Merus is a leader in developing multispecific antibodies with promising lead candidates petosemtamab and zenocutuzumab targeting various cancers. Merus has strong financials, and partnerships with major companies like Gilead, Incyte, and Eli Lilly, but faces risks due to its current valuation and assumptions about pipeline success.
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.66 per share a year ago.
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Merus (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
Merus N.V. is experiencing significant growth and entering a higher price territory, making the risk-reward less clear. The company's bispecific antibody, petosemtamab, showed promising results in a phase 2 study for head and neck squamous cell carcinoma. Merus' other bispecific antibody, zenocutuzumab, has a high chance of approval for NRG1-positive NSCLC and pancreatic cancer, with a decision expected later in 2024.
